Search
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
3 hours ago
SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa
He describes how this dual T-cell agonist is designed to cause the expansion and reprogramming of TIL's in the body. Plus, an update on...
Nov 9, 2024
Immuno-Oncology experts Zhen Su and Kristen Hege discuss the latest in the field and preview #SITC24
Dr. Su and Dr. Hege talk about solving the cell therapy solid tumor challenge, the latest in bi-specifics, her recent hike of the Pacific...
Oct 1, 2024
Marengo Therapeutics' CEO Zhen Su on the expansion of a partnership with Ipsen to activate T-cells against cold tumors
After announcing a partnership expansion with Ipsen on Friday, Zhen Su describes how to succeed against cold tumors where T-cells are not...
Jun 11, 2024
The CEO of Marengo Therapeutics talks about his company's focus on activating and expanding T-cells
Zen Su gives an overview Marengo, his view of #SITC23, and SITC's new biotech initiative.
Nov 4, 2023
.png){kind=logo}
